Health Sciences Review, Journal Year: 2024, Volume and Issue: 10, P. 100165 - 100165
Published: March 1, 2024
Language: Английский
Vaccines, Journal Year: 2025, Volume and Issue: 13(2), P. 191 - 191
Published: Feb. 15, 2025
Using plants as bioreactors, molecular farming has emerged a versatile and sustainable platform for producing recombinant vaccines, therapeutic proteins, industrial enzymes, nutraceuticals. This innovative approach leverages the unique advantages of plants, including scalability, cost-effectiveness, reduced risk contamination with human pathogens. Recent advancements in gene editing, transient expression systems, nanoparticle-based delivery technologies have significantly enhanced efficiency versatility plant-based systems. Particularly vaccine development, demonstrated its potential notable successes such Medicago's Covifenz COVID-19, illustrating capacity platforms to address global health emergencies rapidly. Furthermore, edible vaccines opened new avenues mainly settings low resources where cold chain used conventional logistics is challenge. However, optimization protein yield stability, complexity purification processes, regulatory hurdles are some challenges that still remain. review discusses current status development using operational mechanisms plant platforms, major applications prevention infectious diseases, developments, nanoparticle-mediated cancer vaccines. The discussion will also touch on ethical considerations, framework, future trends respect transformative plant-derived ensuring greater accessibility cost-effectiveness vaccination. field holds great promise disease area and, indeed, personalized medicine biopharmaceuticals near future.
Language: Английский
Citations
1
Nano-Micro Letters, Journal Year: 2025, Volume and Issue: 17(1)
Published: Feb. 21, 2025
The emerging messenger RNA (mRNA) nanomedicines have sprung up for disease treatment. Developing targeted mRNA has become a thrilling research hotspot in recent years, as they can be precisely delivered to specific organs or tissues enhance efficiency and avoid side effects. Herein, we give comprehensive review on the latest progress of with targeting functions. its carriers are first described detail. Then, mechanisms passive targeting, endogenous active outlined, focus various biological barriers that may encounter during vivo delivery. Next, emphasis is placed summarizing mRNA-based organ-targeting strategies. Lastly, advantages challenges clinical translation mentioned. This expected inspire researchers this field drive further development technology.
Language: Английский
Citations
1
Biochemical and Biophysical Research Communications, Journal Year: 2024, Volume and Issue: unknown, P. 150671 - 150671
Published: Sept. 1, 2024
Language: Английский
Citations
1
Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)
Published: Oct. 16, 2024
Vaccination has played a critical role in mitigating COVID-19. Despite the availability of licensed vaccines, there remains pressing need for improved vaccine platforms that provide high protection, safety, and versatility, while also reducing costs. In response to these challenges, our aim is create self-adjuvanted against SARS-CoV-2, utilizing Virus-Like Particles (VLPs) as foundation. To achieve this, we produced bacteriophage (Qβ) VLPs prokaryotic system purified them using rapid cost-effective strategy involving organic solvents. This method aims solubilize lipids components cell membrane eliminate endotoxins present bacterial samples. For formulation, Receptor Binding Domain (RBD) antigens were conjugated chemical crosslinkers, process compatible with Good Manufacturing Practice (GMP) standards. Transmission Electron Microscopy (TEM) confirmed expected folding spatial configuration QβVLPs vaccine. Additionally, formulation assessment involved SDS-PAGE stained Coomassie Brilliant Blue, Western blotting, stereomicroscopic experiments. vitro vivo evaluations conducted assess its capacity induce protective immune without causing side effects. Vaccine doses 20 µg 50 stimulated production neutralizing antibodies. testing, group animals vaccinated provided complete protection virus infection, maintaining stable body weight showing signs disease. conclusion, QβVLPs-RBD proven be effective safe, eliminating necessity supplementary adjuvants offering financially feasible approach. Moreover, this platform demonstrates flexibility targeting Variants Concern (VOCs) via established conjugation protocols VLPs.
Language: Английский
Citations
1
Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15
Published: Nov. 6, 2024
As of December 2020, around 200 vaccine candidates for Coronavirus Disease 2019 (COVID-19) are being developed. COVID-19 vaccines have been created on a number platforms and still Nucleic acid (DNA, RNA) vaccines, viral vector inactivated protein subunit live attenuated among the modalities. At this time, at least 52 candidate studied. Spike is primary that targeting. Therefore, it critical to determine whether immunizations provide complete or fractional protection, varies with age, vaccinated people protected from reoccurring diseases, they need booster shots if they’ve already inoculated. Despite enormous achievement bringing several market in less than year, acquiring herd immunity national level much more so global remains major challenge. we gathered information mechanism action presently available review essential data vaccines’ advantages downsides their future possibilities.
Language: Английский
Citations
1
Health Sciences Review, Journal Year: 2024, Volume and Issue: 10, P. 100165 - 100165
Published: March 1, 2024
Language: Английский
Citations
0